BioMarin Pharmaceutical stock had its Relative Strength (RS) Rating upgraded from 70 to 77 Thursday -- a welcome improvement, but still short of the 80 or better score you look for.
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 as they launch their biggest price moves. See if BioMarin Pharmaceutical stock can continue to show renewed price strength and hit that benchmark.
See How IBD Helps You Make More Money In Stocks
Is BioMarin Pharmaceutical Stock A Buy?
BioMarin Pharmaceutical stock retook its 200-day moving line. Now is not an ideal time to jump into the biotech stock since it isn't near a proper buy zone, but see if the stock is able to form a base and break out. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings growth rose last quarter from 150% to 800%. But sales fell from 24% to 20%. The next quarterly results are expected on or around Apr. 26.
BioMarin Pharmaceutical stock earns the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
